Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa

Autor: S, Boyer, M L, Nishimwe, L, Sagaon-Teyssier, L, March, S, Koulla-Shiro, M-Q, Bousmah, R, Toby, M P, Mpoudi-Etame, N F, Ngom Gueye, A, Sawadogo, C, Kouanfack, L, Ciaffi, B, Spire, E, Delaporte, F, Simon

Publikováno v: PharmacoEconomics-Open
PharmacoEconomics-Open, 2020, 4 (1), pp.45-60. ⟨10.1007/s41669-019-0157-9⟩
PharmacoEconomics-open / Pharmacoecon Open
PharmacoEconomics-open / Pharmacoecon Open, [Cham, Switzerland] : Springer International Publishing AG, [2017]-, 2020, 4 (1), pp.45-60. ⟨10.1007/s41669-019-0157-9⟩
PharmacoEconomics Open
PharmacoEconomics-Open, [Cham, Switzerland] : Springer International Publishing AG, [2017]-, 2020, 4 (1), pp.45-60. ⟨10.1007/s41669-019-0157-9⟩

Background While dolutegravir has been added by WHO as a preferred second-line option for the treatment of HIV infection, boosted protease inhibitor (bPI)-based regimens are still needed as alternative second-line options. Identifying optimal bPI-bas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::52f9b975777637d8129b87d343f6bafe
https://hal.science/hal-02510696/document